KRAS and neoplasm: Tumors of animals harboring hamartin loss and KRAS (G12D) expression in lung epithelial cells revealed 1) reduced tumor latency, 2) an activation of mTOR and 3) a response to treatment with rapamycin with improved survival compared to KRAS alone mutant mice [20].